0000000000354411

AUTHOR

Thomas Nägele

showing 2 related works from this author

The effects of linearly increasing flip angles on 3D inflow MR angiography

1994

As recently demonstrated, spin saturation effects in 3D time-of-flight (TOF) MR angiography (MRA) can be reduced by using RF pulses with linearly increasing flip angles (ramp pulses) in the main direction of flow. We developed a model for calculating the signal distribution of proton flow within the excitation volume (slab) for different ramp slopes and compared the results with the measured distribution for the lower-leg arteries. The ramp pulses were generated using the Fourier transformation of the desired excitation profiles. With a bandwidth of 6 kHz and a pulse length of 2.56 ms satisfactory ramps with variable slopes were generated and applied in a standard flow-compensated 3D FISP s…

Materials scienceInflowsymbols.namesakeNuclear magnetic resonanceHumansPopliteal ArteryRadiology Nuclear Medicine and imagingSaturation (magnetic)Fourier AnalysisModels CardiovascularMr angiographyReproducibility of ResultsPulse durationRangingArteriesImage EnhancementMagnetic Resonance ImagingComputational physicsTibial ArteriesFourier transformFibulaRegional Blood FlowBlood CirculationsymbolsSlabBlood VesselsArtifactsAlgorithmsBlood Flow VelocityExcitationMagnetic Resonance in Medicine
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct